Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 35 citing articles:

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 23
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Friederike Holze, Nirmal Singh, Matthias E. Liechti, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 472-489
Open Access | Times Cited: 20
Adverse Events in Studies of Classic Psychedelics
Jared T. Hinkle, Marianna Graziosi, Sandeep M. Nayak, et al.
JAMA Psychiatry (2024)
Closed Access | Times Cited: 17
Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Wenwen Duan, Dongmei Cao, Sheng Wang, et al.
Chemical Reviews (2023) Vol. 124, Iss. 1, pp. 124-163
Closed Access | Times Cited: 30
Therapeutic mechanisms of psychedelics and entactogens
Boris D. Heifets, David E. Olson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 104-118
Closed Access | Times Cited: 29
Psychedelics in Psychiatry: Oh, What A Trip!
Gregory A. Fonzo, Charles B. Nemeroff, Ned H. Kalin
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 1-5
Closed Access | Times Cited: 1
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 33-46
Closed Access | Times Cited: 1
Ethnoracial inclusion in clinical trials of psychedelics: a systematic review
Marcus Hughes, Albert Garcia‐Romeu
EClinicalMedicine (2024) Vol. 74, pp. 102711-102711
Open Access | Times Cited: 7
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
Drummond E-Wen McCulloch, Matthias E. Liechti, Kim P. C. Kuypers, et al.
Neuroscience Applied (2024) Vol. 3, pp. 103938-103938
Open Access | Times Cited: 5
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e112-e120
Closed Access | Times Cited: 5
The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Stephan C. Tap
Addiction Biology (2024) Vol. 29, Iss. 4
Open Access | Times Cited: 5
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials
Michelle Matvey, D. Parker Kelley, Ellen Bradley, et al.
JAMA Psychiatry (2025) Vol. 82, Iss. 3, pp. 311-311
Closed Access
Classical psychedelics in therapy: Essential psychotherapy or minimal support?
Gitte M. Knudsen
European Neuropsychopharmacology (2025) Vol. 93, pp. 27-28
Closed Access
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment
Metten Somers, Floortje E. Scheepers
American Journal of Psychiatry (2025) Vol. 182, Iss. 3, pp. 243-246
Closed Access
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges
Sharmin Ghaznavi, Steffen Richter
Drugs (2025)
Closed Access
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants
James Rucker, Claire Roberts, Mathieu Seynaeve, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 712-723
Closed Access | Times Cited: 3
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Noah Chisamore, Erica Kaczmarek, Gia Han Le, et al.
Current Treatment Options in Psychiatry (2024) Vol. 11, Iss. 2, pp. 90-105
Closed Access | Times Cited: 3
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials
Aleksander Kwaśny, Alina Wilkowska, Wiesław Jerzy Cubała
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Psychedelics for treatment resistant depression: are they game changers?
Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 2117-2132
Open Access | Times Cited: 8
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Haley Maria Dourron, Charles D. Nichols, Otto Simonsson, et al.
Psychopharmacology (2023)
Closed Access | Times Cited: 8
The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness
Frankie A. Colosimo, Philip Borsellino, Reese I. Krider, et al.
Psychoactives (2024) Vol. 3, Iss. 1, pp. 93-122
Open Access | Times Cited: 2
Psychedelika in der Psychiatrie
Uwe Herwig
Nervenheilkunde (2024) Vol. 43, Iss. 05, pp. 236-241
Closed Access | Times Cited: 2
The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression
Marcelo Falchi, Handersson Barros, Raynara Bolcont, et al.
Psychedelic Medicine (2024)
Closed Access | Times Cited: 2
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner.
Miguel Farinha‐Ferreira, Catarina Miranda‐Lourenço, Chloé Galipeau, et al.
Neuropharmacology (2024) Vol. 266, pp. 110280-110280
Closed Access | Times Cited: 2
A dual-receptor model of serotonergic psychedelics
Arthur Juliani, Veronica Chelu, Laura Graesser, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top